Bevacizumab in the Treatment of Neovascular Glaucoma
No Thumbnail Available
Date
2020
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Bevacizumabs ir anti-VEGF līdzeklis, ko lieto kā nenorādītu indikāciju neovaskulāras glaukomas ārstēšanā. Neovaskulārā glaukoma ir sekundāras glaukomas forma, ko bieži izraisa proliferatīvā diabētiskā retinopātija un tīklenes centrālo vēnu oklūzija, kā rezultātā rodas tīklenes išēmija un pēc tam atbrīvojas asinsvadu endotēlija augšanas faktors (VEGF). Bevacizumaba darbības mehānisms ir saistīt un inhibēt VEGF darbību tā, lai tas neuzsāktu neovaskularizācijas kaskādi acī. To panāk, injicējot bevacizumabu tieši acī vai nu intravitreāli, vai intrakamerāli. Lai gan ir pieejami arī citi anti-VEGF līdzekļi, kas ir apstiprināti lietošanai acīs, bevacizumabu klīnicisti joprojām plaši izmanto daudzu iemeslu dēļ, galvenokārt tāpēc, ka tam ir ļoti maz zināmu blakusparādību, tas strauji samazina neovaskularizāciju un tam ir daudz lētāka cena nekā citām pieejamām aģenti.
Bevacizumab is an anti-VEGF agent used as an off-label indication in the treatment of neovascular glaucoma. Neovascular glaucoma is a form of secondary glaucoma often caused by proliferative diabetic retinopathy and central retinal vein occlusion, which results in retinal ischemia and subsequent release of vascular endothelial growth factor (VEGF). Bevacizumabs mechanism of action is to bind and inhibit action of VEGF so that it will not initiate the cascade of neovascularization within the eye. This is achieved by injecting bevacizumab directly into the eye either intravitreally or intracamerally. Although there are other anti-VEGF agents available and approved for ocular use, bevacizumab is still widely used by clinicians for many reasons, mainly that it has very few known side effects, it rapidly decreases neovascularization and it has a much cheaper price than other available agents.
Bevacizumab is an anti-VEGF agent used as an off-label indication in the treatment of neovascular glaucoma. Neovascular glaucoma is a form of secondary glaucoma often caused by proliferative diabetic retinopathy and central retinal vein occlusion, which results in retinal ischemia and subsequent release of vascular endothelial growth factor (VEGF). Bevacizumabs mechanism of action is to bind and inhibit action of VEGF so that it will not initiate the cascade of neovascularization within the eye. This is achieved by injecting bevacizumab directly into the eye either intravitreally or intracamerally. Although there are other anti-VEGF agents available and approved for ocular use, bevacizumab is still widely used by clinicians for many reasons, mainly that it has very few known side effects, it rapidly decreases neovascularization and it has a much cheaper price than other available agents.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
Bevacizumabs, anti-VEGF, neovaskulāra glaukoma, Avastin, intravitreāla bevacizumabs, Bevacizumab, anti-VEGF, Neovascular Glaucoma, Avastin, intravitreal bevacizumab